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Abstract
Background: Exocrine pancreatic insufficiency (EPI) is characterized by a deficiency of exocrine pancreatic enzymes,
resulting in malabsorption. Numerous conditions account for the etiology of EPI, with the most common being
diseases of the pancreatic parenchyma including chronic pancreatitis, cystic fibrosis, and a history of extensive
necrotizing acute pancreatitis. Treatment for EPI includes dietary management, lifestyle changes (i.e., decrease in
alcohol consumption and smoking cessation), and pancreatic enzyme replacement therapy.
Discussion: Many diagnostic tests are available to diagnose EPI, however, the criteria of choice remain unclear and
the causes for a false-positive test are not yet understood. Despite multiple studies on the treatment of EPI using
exogenous pancreatic enzymes, there remains confusion amongst medical practitioners with regard to the best
approach to diagnose EPI, as well as dosing and administration of pancreatic enzymes.
Summary: Appropriate use of diagnostics and treatment approaches using pancreatic enzymes in EPI is essential
for patients. This opinion piece aims to address the existing myths, remove the current confusion, and function as a
practical guide to the diagnosis and treatment of EPI.
Keywords: Exocrine pancreatic insufficiency, Lipase, Steatorrhea, Fat malabsorption, Pancreatic enzyme replacement
therapy, Pancreatic enzymes
Background
Exocrine pancreatic insufficiency (EPI) is defined by a
deficiency of exocrine pancreatic enzymes resulting in
an inability to maintain normal digestion. This inad-
equate digestion with nutrient and, especially, fat malab-
sorption occurs when intraduodenal levels of lipase fall
below 5–10% of normal enzyme output [1], leading to
pancreatic steatorrhea, weight loss, and a potential de-
crease in quality of life [2–5]. Furthermore, in EPI, due
to cystic fibrosis (CF) or chronic pancreatitis, there is
decreased bicarbonate output causing a lower intestinal
pH, which precipitates bile salt acids and impairs micelle
formation of fats [6, 7]. Fat maldigestion is compounded
by decreased pancreatic secretion of lipase and colipase,
further dampening hydrolysis of intraluminal fat.
A myriad of tests for EPI have been developed over
the years, however, the choice of which to use remains
unclear as does the understanding of causes for a false-
positive test. In addition, there is significant confusion
over dosing and administration of pancreatic enzymes.
This opinion piece aims to address the existing myths,
remove the current confusion, and function as a prac-
tical guide to the diagnosis and treatment of EPI.
Discussion
Myth: EPI occurs only with more than 90% loss of
exocrine pancreatic function
Expert opinion: EPI represents a graded response
rather than a precise cut-off in pancreatic function
and thus patients may benefit from early testing
A leading cause of EPI is chronic pancreatitis [8].
Other pancreatic causes include a history of extensive
necrotizing acute pancreatitis, pancreatic cancer, pancre-
atic surgery, and CF. Non-pancreatic causes are celiac
disease, diabetes mellitus, Crohn’s disease, gastric sur-
gery, short bowel syndrome, and Zollinger–Ellison syn-
drome [9]. Symptoms of EPI can include steatorrhea
(clay-colored, loose, greasy, foul-smelling large stools),
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abdominal discomfort, bloating, and weight loss. Al-
though floating stools are often thought of being indica-
tive of steatorrhea, they are not; rather sticking to the
toilet bowl is a more specific sign.
Chronic pancreatitis
Chronic pancreatitis is an ongoing inflammatory process
with irreversible morphological changes to the pancreas
and a gradual loss in pancreatic parenchyma. There are
three major groups of mutations that account for
chronic pancreatitis (PRSS1, SPINK1, and CFTR). The-
ories of pathogenesis include oxidative stress, toxic-
metabolic derangements, loss of ductal function or
obstruction, and necrosis-fibrosis [10].
In chronic pancreatitis, approximately 20% of patients
develop EPI over time as a result of progressive loss of
acinar cell function [11]. Layer et al. [11] found that the
median duration from the onset of symptomatic disease
to EPI was significantly longer in early-onset chronic
pancreatitis (median age of onset being 19.2 years) than
in late-onset idiopathic chronic pancreatitis (median age
of 56.2 years) or alcoholic pancreatitis (median age of
13.1 years).
Cystic fibrosis
CF is an autosomal recessive disorder caused by a muta-
tion of the gene that encodes for a chloride channel
called the cystic fibrosis transmembrane conductance
regulator (CFTR). In ductal epithelial cells, CFTR is
highly expressed and functions to transport fluid and an-
ions into the lumen [12]. Dysfunction of the CFTR gene
leads to a decrease in luminal fluid volume and de-
creased pH, resulting in protein precipitation within the
ductal lumen and loss of normal acinar cell function.
EPI is most commonly observed at birth or soon after
due to in utero exocrine pancreatic damage. Waters et
al. [13] showed that, during newborn screening, 63% of
infants with CF are exocrine insufficient and almost 30%
of the pancreas-sufficient group will become exocrine
insufficient over the next 36 months. Individuals with
class IV, V, or VI mutations (less severe CFTR mutations
and hence some preserved CFTR function), tend to suf-
fer from EPI later in life [14, 15]. Corey et al. [16] com-
pared 1000 patients from CF clinics in Boston and
Toronto and demonstrated that prolonged untreated
EPI is associated with a worse long-term outcome and
that patients maintained on a high fat diet (100 g per
day) with higher doses of exogenous pancreatic enzymes
did better than those on a low fat, lower pancreatic en-
zyme regimen. Overall, pancreatic insufficiency requiring
lifelong pancreatic exocrine replacement therapy (PERT)
is found in about 85% of CF patients [12].
A rare complication of PERT is seen only in patients
with CF on very high doses of enzymes. Fitzsimmons et
al. [17] found that, in children with CF, there was a
strong correlation between high daily doses of PERT and
the development of fibrosing colonopathy. However, this
represents a small case series published in NEJM in
1997, which were not biopsy proven with very few cases
reported since then. Factors related to CF, including
thick intestinal secretions, dosing of PERT, and agents in
the enteric coating of the pancrelipase preparations may
be the precipitating factors causing this complication
[18]. Therefore, it has been recommended that, in chil-
dren and adults with CF, the daily dose should remain
below 2500 lipase units/kg of body weight per meal or
10000 lipase units/kg of body weight per day [17, 19].
Post pancreatic surgery
Factors that contribute to EPI following pancreatic sur-
gery are a decrease in pancreatic tissue volume, exten-
sive denervation following lymph node dissection, and
surgically altered anatomy [6]. Conditions such as
pancreatic cancer, intraductal papillary mucinous neo-
plasms, premalignant mucinous cystic lesions, and be-
nign tumors of the pancreas may all lead to EPI via
obstruction of the pancreatic duct. The degree of EPI
following pancreatic surgery is dependent on the extent
of pancreatic resection combined with the degree of re-
sidual pancreatic parenchymal function with full mani-
festation of EPI seen following a total pancreatectomy
[20, 21]. The mechanism of EPI in patients undergoing a
Whipple procedure may be related to a mistiming of
secreted endogenous pancreatic enzymes mixing with
chyme.
Large systematic reviews report a 19–80% incidence of
EPI following a distal pancreatectomy [22–25]; however,
this wide variation may be in part a result of the
different diagnostic methods employed [22, 26]. Post-
operative incidence of EPI after Whipple surgery is 56–
98% [23, 24, 27–29]. In addition, Halloran et al. [28]
analyzed 40 patients following resection for pancreatic
malignancy and found that EPI was common and sus-
tained after surgery, but was not associated with signifi-
cant symptoms. These patients with newly developed
EPI, however, did have a tendency towards poorer qual-
ity of life.
Celiac disease
Celiac disease is a chronic inflammatory intestinal dis-
order that may occur in genetically predisposed people
triggered by the ingestion of gluten. This disease has a
United States and British prevalence of approximately
1% [30, 31]. In celiac disease, although exocrine pancre-
atic function is intrinsically normal, reduced levels of
cholecystokinin release as a result of the duodenal vil-
lous atrophy, accounts for impaired gall bladder contrac-
tion and reduced exocrine pancreatic secretion [32, 33].
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Diabetes mellitus
The term islet-acinar axis has been used to describe the
endocrine-exocrine relationship within the pancreas,
whereby there is a vascular and physiologic interaction
between these different cell types [34]. Pathophysiologic-
ally, diabetes mellitus can predispose to EPI and, con-
versely, longstanding EPI can be associated with diabetes
[35–39]. In diabetes, there are several possible causes
which can account for EPI – the lack of the trophic action
of insulin (and potentially of glucagon and somatostatin)
on acinar cells, autoimmune damage of islet cells, causing
destruction of both endocrine and exocrine tissue, and de-
creased exocrine pancreatic secretion as a complication of
diabetic neuropathy [36, 37]. Therefore, the lack of insulin
production and the autoimmunity in type I diabetes ex-
plain the higher observed prevalence of EPI compared to
those with type II diabetes (about 60% vs. 30%) [38]. In
addition, a recent article by Soave et al. [39] showed that
the lower the immunoreactive trypsinogen levels at birth
in newborns with CF, reflecting more severe exocrine pan-
creatic disease in utero, the earlier in life they developed
CF-related endocrine disease (diabetes).
All infants
Based on the study by Lebenthal and Lee [40] indicating
that the duodenal fluid of newborns and infants con-
tained no amylase and negligible lipase at least for the
first month of life, all healthy term infants are exocrine
pancreatic insufficient. Normally, this is compensated
for by amylase and lipase present in breastmilk. How-
ever, in formula-fed infants, EPI would be expected. In
fact, a recent study by Martin et al. [41] confirmed that
formula-fed preterm infants had impaired fatty acid ab-
sorption evident through 6 or more weeks postnatal age
compared to breastmilk-fed infants, and this is consist-
ent with limited pancreatic lipase production by the pan-
creas [41]. Thus, all infants, both term and preterm,
represent the largest population of individuals with EPI.
The clinical implications of developmental pancreatic in-
sufficiency in non-breast-fed infants is unknown, but
may play a role in early nutrient deficits in critically ill
newborns such as the preterm infant.
How do we test for exocrine pancreatic insufficiency?
Myth: Routinely checking for EPI in patients with
chronic diarrhea, using fecal elastase, is a useful and
effective diagnostic approach with values 100–200 μg/g
of stool reflecting mild to moderate pancreatic
insufficiency and 100 μg/g of stool indicating severe EPI
Expert opinion: Routinely checking for EPI in patients
with chronic diarrhea, using fecal elastase, is
unreliable in the absence of testing a formed stool
A multitude of tests for EPI have been developed over
the past several decades and classified as direct versus
indirect measures of exocrine pancreatic function. How-
ever, many of these have poor sensitivity or specificity
(e.g. serum trypsin levels, qualitative stool fat) and/or are
available at only limited centers such as with the 13C
mixed triglyceride (13C-MTG) breath test.
72-hour fecal fat test
The gold standard has been the 72-hour stool collection
while the patient consumes a diet containing 100 g of fat
per day. Fat malabsorption is diagnosed at > 7 g of fat
per 100 g of stool per day, with severe steatorrhea
at ≥ 15 g per day [18]. Unfortunately, this test is time-
consuming and not easily tolerated due to bloating,
abdominal discomfort, flatulence, and worsening stea-
torrhea. Additionally, errors can occur in stool collec-
tions and recording of fat intake [42]. Diseases that
impact mucosal fatty acid uptake, such as Crohn’s
disease, bacterial overgrowth, and short bowel syn-
drome, can cause abnormal values despite normal
exocrine pancreatic function. However, the 72-hour
stool collection has served to measure the effective-
ness of PERT in EPI [43] for United States Food and
Drug Administration (FDA) approval of PERTs.
Fecal elastase test
The pancreas produces pancreatic elastase 1, which is a
highly stable enzyme during intestinal transit [44]. This
proteolytic enzyme can be measured in a fecal sample by
an enzyme-linked immunosorbent assay [45, 46]. Be-
cause pancreatic elastase is highly stable during intes-
tinal transit, the fecal concentration correlates well with
exocrine pancreatic secretion [45]. Diagnostic testing
using fecal elastase has some advantages over other tests
because it does not require a timed stool collection or
special diet, has a high negative predictive value, and has
a high sensitivity in moderate to severe EPI when
formed stools are analyzed [8, 42, 47, 48]. The reference
range of less than 200 μg/g feces can be applied to both
children and adults for the diagnosis of EPI [44, 45, 49].
Some consider values less than 100 μg/g feces as
diagnostic of EPI, with fecal elastase values between
100 and 200 μg/g to be indeterminate and difficult to
interpret [50].
In mild to moderate EPI, diagnostic testing using fecal
elastase has a lower sensitivity (as low as 30%) and speci-
ficity, possibly resulting in an underestimation of EPI
[45, 51–53]. In childhood, however, fecal elastase is a
useful noninvasive screening test for EPI, demonstrating a
negative predictive value of 99% for ruling out EPI [42].
Since fecal elastase is measured as a concentration in
stool, watery stools will almost invariably result in low
elastase values being measured and thus this non-invasive,
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pancreatic function test should be performed in a clinical
setting where EPI is suspected and a formed stool can be
analyzed. This has replaced the more cumbersome 72-
hour fecal fat test. In addition, PERTs do not have to be
stopped for fecal elastase testing since the porcine en-
zymes do not cross react with the human fecal elastase
antibody.
Treatment of exocrine pancreatic insufficiency
Myth: PERT should be started at the lowest dose
available and taken any time before a meal and at
bedtime
Expert opinion: Titrate the dose of PERT to the
presumptive degree of PERT and administer PERT
with the first bite of a meal, and consider adding extra
enzymes during or towards the end of the meal
Dietary management and lifestyle changes
Fat malabsorption is the predominant cause of the
symptoms of pancreatic steatorrhea resulting in weight
loss as well as deficiencies of fat-soluble vitamins A, D,
E, and K. In patients with chronic pancreatitis, a low fat
diet has been the recommendation in order to minimize
the pain of this disease and, in conjunction with PERT,
to effectively treat steatorrhea. However, in patients with
CF, a high fat diet in conjunction with increased
amounts of PERTs has been shown to improve the asso-
ciated CF lung disease and thus low fat diets are no lon-
ger advocated in this disease. Fat soluble vitamins A, D,
E, and K should be supplemented if indicated, and taken
with PERT [54]. Consulting a dietitian is helpful to as-
sess nutritional adequacy [55]. In addition, smoking has
been proven to be a risk factor in acute pancreatitis,
chronic pancreatitis, pancreatic cancer [56], and to be
associated with reduced exocrine pancreatic function
[57]. Therefore, smoking and alcohol cessation is recom-
mended in EPI due to chronic pancreatitis.
Pancreatic enzyme replacement therapy
The elimination of malabsorption, reduction of
maldigestion-related symptoms, and the prevention of
malnutrition-related morbidity and mortality is the goal
for PERT [55]. This is most evident in CF, where prior
to the availability of PERT, infants died within the first
year of life. Prior to 2010, pancreatic enzymes were not
FDA regulated and had variable consistency of activity.
As a result, in 2010, the FDA mandated approval of
all prescribed formulations of PERT. It should be
noted that the clinical trials were relatively small (less
than 40 subjects) and tested in subjects who were
known to respond to PERTs. All pancreatic enzyme prepa-
rations are extracts from porcine pancreas (pancrelipase)
and are available in preparations encapsulated in mini-
microspheres or microtablets, which vary in particle size
and pH-related release kinetics [58]. Enteric-coated pan-
creatic microspheres are designed to be acid resistant and
pH-sensitive to protect lipase from denaturation by gastric
acid. Unfortunately, confusion has arisen due to the many
different dosage strengths of PERTs [59] (Table 1).
Enteric-coated pancreatic enzymes are most effective
at a pH > 6. However, in patients with CF, the duodenal
pH is < 6 [60]. The use of acid-suppression medications
can increase gastric pH levels and theoretically improve
the efficacy of PERT and decrease EPI symptoms [61, 62].
Current data may suggest a trial of acid blockers in pa-
tients with CF who have refractory steatorrhea [61–65].
However, a recent retrospective study demonstrated no
improvement of the coefficient of fat absorption (72-hour
fecal fat test) when using a proton pump inhibitor in
pediatric patients with CF [66].
Uncoated exogenous pancreatic enzymes, such as
Viokase (Aptalis Pharma), are thought to mix well with
intragastric nutrients and rapidly release high duodenal
lipase amounts for fat digestion [58]. The addition of
acid-suppression medications is required to prevent deg-
radation of non-enteric coated pancreatic enzymes [58].
Only non-enteric pancreatic enzymes have been shown
to improve the pain in a subset of patients with chronic
pancreatitis. The use of unprotected exogenous enzymes
in combination with enteric-coated enzymes has previ-
ously been recommended for the treatment of refractory
EPI [58, 67]; however, Kalnins et al. [68] showed no im-
provement in nutrient digestion (fecal fat, energy, and
nitrogen output) when unprotected pancreatic enzymes
were added to the conventional enteric-coated enzymes
in 14 pediatric patients with CF.
Dosing and frequency of PERT administration
Dosing and frequency of administration are difficult
aspects of PERT treatment since different enteric-
coated microspheres are not bioequivalent in vitro
[69–71], and there are not enough clinical studies be-
tween preparations to define in vivo bioavailability. In
these in vitro studies, the preparations varied in
Table 1 Current Food and Drug Administration (FDA) approved
pancreatic enzyme replacement therapies (PERTs)
Brand Units of lipase
Creon 3000; 6000; 12,000; 24,000; 36,000
Zenpep 3000; 5000; 10,000; 15,000; 20,000; 25,000
Pancreaze 4200; 10,500; 16,800; 21,000
Ultresa 13,800; 20,700; 23,000
Viokase 10,440; 20,880 (requires acid suppression)
Pertzye 8000; 16,000
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dissolution time (49–71 min half-life time) and in
optimum pH (pH 5.0–5.8).
Several countries have recommended different doses
of PERT. The Australasian Pancreatic Club [72], The
Italian Association for the Study of the Pancreas [8], and
The Spanish Pancreatic Club [73] recommend 25,000–
50,000 lipase units per main meal in adults. Unfortu-
nately, the evidence for these recommendations is
relatively weak as emphasized by The Australasian
Pancreatic Club in their recent study on the manage-
ment of pancreatic exocrine insufficiency [72]. In
addition, a study from the Netherlands by Sikkens et al.
[74] found that 70% (n = 161) of the patients with EPI
caused by chronic pancreatitis were under-treated and
reported steatorrhea-related symptoms, despite PERT
(median enzyme intake of 6 capsules, 25,000 lipase units
per day). These differences in recommendations demon-
strate the significant confusion over dosing and adminis-
tration amongst medical practitioners.
Likewise, there is no consensus over frequency of
PERT administration. In 1977, DiMagno et al. [75] dem-
onstrated that administration of PERT during a meal
was as effective as hourly administration over the day to
decrease steatorrhea. Other recommendations based on
several reviews are to take 50% of the exogenous pan-
creatic enzymes at the beginning of the meal and 50%
half-way through [76], pancreatic enzymes during or
immediately following the meal [77], or lastly, 25% of
the enzymes with the first bite, 50% during the meal,
and 25% with the last bite [78]. In addition, a recent
randomized three-way crossover study of 24 patients
using 40,000 lipase units per meal compared three dif-
ferent administration schedules with PERT before
meals, during meals, or after meals using the 13C-MTG
breath test to measure fat absorption [79]. The percent-
age of patients who normalized fat digestion was 50%,
54%, and 63%, respectively. Thus, no statistically signifi-
cant differences were found between different adminis-
tration schedules, however, they did recommend giving
PERT during or after meals.
In a patient with suspected EPI with a known history of
pancreatic disease, empiric therapy with PERTs may be in-
dicated without formal testing. A clear response would be
both diagnostic for EPI as well as therapeutic. In addition,
if there is a poor response to PERT, one should consider
concurrent gastrointestinal comorbidities such as lactose
intolerance, enteric bacterial infection, parasites (especially
giardia), small intestinal bacterial overgrowth, biliary dis-
ease (cholestasis), colitis, celiac disease, short bowel syn-
drome, and Crohn’s disease [80]. Other reasons could be
insufficient dosing, lack of compliance, inadequate timing
of PERT administration, and poor diet (Table 2).
PERT should be taken with the first bite of a meal and
consider adding extra enzymes during or towards the
end of the meal. Thus, if consumption of a meal is less
than 15 min, all enzymes can be taken at the beginning
of the meal; for a 15- to 30-minute meal, we suggest tak-
ing half the enzyme capsules with the first bite and the
other half in the middle of the meal; for more than
30 minutes, we recommend taking one third at the be-
ginning, one third in the middle and one third at the
end. The rationale for taking pancreatic enzymes
throughout the meal is to mimic the action of our own
endogenous pancreatic enzymes, where secretion from
the gland occurs throughout a meal. Specifically, the
more food that is ingested and/or the grater the amount
of fat in the diet, the higher the amount of endogenous
pancreatic enzyme secretion; thus, the number of PERT
capsules consumed should reflect this. Table 3 gives a
suggested clinical overview of PERT dosing for different
age groups [17, 19, 80].
Summary
Since the required FDA approval of PERT in 2010, we
now have reliable medications for the treatment of EPI.
These therapies have improved signs and symptoms re-
lated to EPI such as steatorrhea and abdominal discom-
fort, weight loss, malnutrition, and possibly even quality
of life. PERT is lifesaving in CF, since prior to PERT, ba-
bies with CF died of malnutrition within the first year of
life. However, there is still much confusion amongst
Table 2 Treatment strategies for lack of response to pancreatic
enzyme replacement therapy (PERT)
Treatment strategies
• Increase dosage
• Check compliance with the patient
• Add acid inhibitor
• Consider adding enzymes during and towards end of meal
• Consider microspheres, possibly adding a rapid release enzyme
preparation
• Look for evidence of concurrent gastrointestinal disorder
Table 3 Pancreatic enzyme replacement therapy (PERT)
suggested dosing in different age groups
Age group Units of lipase
Infant 2000–4000 units/120 mL formula
or breastmilk
Child age < 4 years 1000 units/kg/meal
500 units/kg/snack
Child age≥ 4 years 500 units/kg/meal
250 units/kg/snack
Adult starting dose 50,000 units/meal
25,000 units/snack
Adult maximum dose 150,000 units/meal
70,000 units/snack
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medical practitioners over the best diagnostic approach
as well as dosing and administration of PERT. Many
countries have developed different guidelines regarding
dosing and administration of PERT, calling out for a
consensus and a practical guide for the diagnosis and
treatment of EPI using exogenous pancreatic enzymes.
In addition, evidence supports that patients are being
undertreated with PERT and may potentially benefit
from more adequate therapy.
There are two areas that need emphasis. First, physi-
cians need to know when to test for EPI and agree on
using the same methods for diagnosing EPI. Over the
last decade, there has been a change in diagnostic ap-
proach for EPI from the unreliable qualitative stool test
and the cumbersome 72-hour fecal fat collection, to the
more sensitive, but less specific, fecal elastase test, espe-
cially in patients with mild to moderate EPI. Many phy-
sicians do not realize the need to have formed stools
analyzed and thus, in chronic diarrhea, this may be
problematic. Ultimately, what is critical is the early diag-
nosis and optimization of treatment of EPI.
Second, there must be optimization of the currently
available therapies for EPI. The existing studies vary on
recommendations for dosing of exogenous pancreatic
enzymes ranging from 25,000 to 80,000 lipase units per
main meal, and there is uncertainty about administration
of PERT before, during, or after the meal. In addition,
the treatment goals differ from reducing pancreatic stea-
torrhea and elimination of maldigestion and malabsorp-
tion, to the prevention of malnutrition-related morbidity
and mortality. This is all complicated by the myriad of
pancreatic enzyme formulations at a wide array of dos-
ing strengths. Thus, it is not surprising that confusion
amongst physicians exists over the optimal dosage, ad-
ministration schedule, and what to aim for in PERT.
Our recommendations for PERT are: (1) titrate the dose
of PERT to the presumptive degree of PERT, (2) adminis-
ter PERT with the first bite of a meal and consider adding
extra enzymes during or towards the end of the meal,
(3) consider using microspheres, possibly adding a
rapid release enzyme preparation and/or acid-blockade,
and (4) adjusting the dose to the fat content of the meal.
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